From: The EMPA-REG outcome study: critical appraisal and potential clinical implications
 | Empagliflozin (all together) | Placebo | HR 95 % CI | Non inferiority | Superiority |
---|---|---|---|---|---|
Primary endpoint | 490/4687 (10.5 %) | 282/2333 (12.1 %) | 0.86 0.74–0.99 | P < 0.001 | P = 0.04 |
Key secondary endpoint | 599/4687 (12.8 %) | 333/2333 (14.3 %) | 0.89 0.78–1.01 | P < 0.001 | P = 0.08 |
 Cardiovascular death | 172/4687 (3.7 %) | 137/2333 (5.9 %) | 0.62 0.49–0.77 | N.A. | P < 0.001 |
 Non-fatal myocardial infarction | 213/4687 (4.5 %) | 121/2333 (5.2 %) | 0.87 0.70–1.09 | N.A. | P = 0.22 |
 Non-fatal stroke | 150/4687 (3.2 %) | 60/2333 (2.6 %) | 1.24 0.92–1.67 | N.A. | P = 0.16 |
Heart failure | 126/4687 (2.7 %) | 95/2333 (4.1 %) | 0.65 0.50–0.85 | N.A. | P = 0.002 |
All-cause death | 269/4687 (5.7 %) | 194/2333 (8.3 %) | 0.68 0.57–0.82 | N.A. | P = 0.001 |